Comparing the current results to its competitors, Zyversa Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13 %, recorded in the same quarter.
Zyversa Therapeutics Inc , slower than the average decrease reported by the company's competitors of -16.63 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -16.63 %
Zyversa Therapeutics Inc 's Comment on Competition and Industry Peers
The pharmaceutical and biotechnology industry includes numerous public and private companies, universities, governmental agencies, and research organizations developing products similar to the company's candidates. Competitors often possess greater financial, technical, and human resources, potentially enabling them to develop, manufacture, and market products more effectively. Competitive factors include product efficacy, safety, ease of use, price, cost-effectiveness, marketing, stakeholder support, service, reputation, and access to technical information. Several companies have drugs in clinical development for focal segmental glomerulosclerosis (FSGS) targeting inflammation, hypertension, and fibrosis, with products in Phase 2 and Phase 3 development. The company states that VAR 200 may be the only drug currently in development targeting lipotoxicity and could be used in combination with other treatments addressing different pathogenic pathways.
November 5, 2024
The rising prevalence of obesity and its associated metabolic complications poses a significant public health challenge globally. The underlying mechanisms contributing to the transition from obesity to insulin resistance and type 2 diabetes are complex and multifaceted, with recent research highlighting the pivotal role of inflammasome-driven inflammation. ZyVersa Therapeutics, Inc. a clinical stage specialty biopharmaceutical company, has made strides in this area, particularly with its development of the first-in-class Inflammasome ASC Inhibitor IC 100. This article reviews the recently published findings demonstrating the effects of inflammasome inhibition on pancreatic islet beta cell protection and the...
July 29, 2024
In recent years, the biomedical community has increasingly recognized the role of inflammasomes in various diseases. ZyVersa Therapeutics, a burgeoning biotechnology company, has been at the forefront of this research, taking notable strides in the development of inflammasome inhibitors. Recent publications highlight their progress, indicating a pivotal moment not just for the company, but also for the broader medical landscape. Groundbreaking Research Early Cognitive Decline BiomarkerZyVersa Therapeutics recently announced significant findings related to their study of inflammasome ASC (Apoptosis-associated Speck-like protein containing a CARD) as a biomarker for early cognitive changes in older adults. Th...
July 25, 2024
ZyVersa Therapeutics, Inc., a pioneering biopharmaceutical company based in Weston, Florida, has made a strategic decision to position obesity and its associated metabolic complications as the primary indication for its promising drug candidate, Inflammasome ASC Inhibitor IC 100. This decision marks a significant leap in the company’s mission to develop innovative treatments for inflammatory and renal diseases, signaling a proactive approach to addressing the global healthcare challenge posed by obesity.Obesity has emerged as a critical public health issue, often leading to a constellation of metabolic disorders, including type 2 diabetes, cardiovascular diseases, and fatty liver disease. The complexities ...
July 18, 2024
Restoration of Retinal Function and Potential Treatments for Diabetes: ZyVersa Therapeutics Advances in Inflammasome InhibitionZyVersa Therapeutics, a biopharmaceutical company focused on developing innovative therapies for various disorders, has made significant progress in the field of inflammasome inhibition. The company recently published findings that demonstrate the efficacy of their inflammasome ASC inhibitor IC 100 in restoring retinal structure and function in a retinopathy of prematurity (ROP) animal model.Retinopathy of prematurity is a potentially blinding disorder that affects premature infants. It is characterized by abnormal blood vessel growth in the retina, leading to retinal scarring and im...
February 29, 2024
In recent years, there has been a growing interest in exploring the therapeutic potential of inflammasome inhibitors for the treatment of various inflammatory and renal diseases. Excitement surrounding the latest developments in this field reached new heights following the announcement by NodThera that their NLRP3 inflammasome inhibitors could effectively treat obesity with weight loss efficacy comparable to Wegovy, a GLP-1 receptor agonist. This groundbreaking news quickly spread like wildfire, garnering attention from both investors and the medical community alike. ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company, was among the companies that experienced a surge in stock prices du...
February 28, 2024
In recent years, there has been a growing understanding of the detrimental role of inflammation in various conditions, including obesity, neurological diseases, and Alzheimer s Disease (AD). Ascending research in this field has shed light on the involvement of inflammasomes, particularly ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain), and ASC specks in triggering and amplifying damaging inflammation. This article explores the findings of three comprehensive review articles by ZyVersa Therapeutics, published in renowned scientific journals, which highlight the therapeutic potential of targeting ASC and ASC specks to attenuate inflammation in obesity, neurological disease...
February 14, 2024
Neurological diseases present an immense burden on global healthcare systems, accounting for an increasing number of disability-adjusted life years. Mounting evidence suggests that dysregulated immune responses, specifically inflammation, are key contributors to the development and progression of various neurological disorders. Inflammasomes, innate immune signaling platforms, have recently gained significant attention due to their involvement in the pathogenesis of numerous diseases. This review aims to provide a comprehensive analysis of inflammasome activation, with a specific focus on the role of inflammation resulting from multiple inflammasome types and the formation of ASC specks in the pathogenesis o...
Recent research conducted by ZyVersa Therapeutics has shed light on the significant role of AIM2 and NLRP3 inflammasomes in promoting the development of atherosclerosis, specifically in diabetic mice. This groundbreaking study also supports the therapeutic rationale of targeting ASC (apoptosis-associated speck-like protein containing a CARD) as a means to inhibit multiple inflammasome pathways involved in atherosclerotic lesion formation. This finding is of paramount importance for healthcare professionals aiming to tackle the intricate relationship between diabetes, inflammation, and cardiovascular complications. Insights into Inflammasomes and Atherosclerosis: Inflammasomes are intricatel...
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Sources:
Zyversa Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zyversa Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
